You can buy Lucielace at the lowest price in the online pharmacy Nextgen.ooo . Elacestrant is an estrogen receptor antagonist used to treat ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression after at least one line of endocrine therapy. Elacestrant is a non-steroidal small molecule and an estrogen receptor (ER) antagonist. It was approved by the FDA in January 2023 for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. It received similar approval in the EU in September 2023.
 
Elacestrant binds to estrogen receptor alpha (ERα) and acts as a selective estrogen receptor degrader (SERD) due to its ability to block the transcriptional activity of the ER and promote its degradation. Other types of endocrine therapy, such as selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs), can lead to drug resistance over time; therefore, the use of SERDs represents a therapeutic approach to the treatment of endocrine-resistant breast cancer. Unlike fulvestrant, another FDA-approved SERD, elacestrant is orally bioavailable.